Figure 2.

(A) Mode of action of empagliflozin, a SGLT2 inhibitor, in the kidneys. (B) The main results of the EMPA-REG trial on cardiovascular outcomes in patients with type 2 diabetes (adapted from³⁰⁾).

EMPA-REG = Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; HF = heart failure; n.s. = not significant; SGLT2 = sodium-glucose cotransporter-2.

^*Death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, ^†Excluding fatal stroke, ^‡p value for test of superiority.